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 Abstract 
Clinical Practice Guideline for Thromboembolism 
Angela Miller MSN, FNP-BC, ONP-C 
 
Background:  The morbidity associated with venous thromboembolism often goes 
unrecognized.  Identifying patient populations at risk for venous thromboembolism and 
implementing evidence-based guidelines can decrease the number of untoward effects of this 
disease.  Clinical pathway guidelines are valuable tools needed by nurses in the prevention and 
treatment of disorders for patients.  Education of the guideline can increase knowledge and 
understanding of what prevention, interventions, and treatment are available for the orthopaedic 
patient and how to apply this knowledge to everyday patient care. 
 
Objective: To educate orthopaedic nurses on the clinical practice guidelines of 
thromboembolism. 
 
Method:  Incorporate the education of thromboembolism in an orthopaedic class intended for 
registered nurses studying for the national orthopaedic exam.   
 
Population: Twenty-three registered nurses from the Mid-Ohio Valley employed at Selby 
General Hospital. 
 
Expected Outcome:  To calculate a statistically difference in the scores of a pre test and a post 
test given to the nurses enrolled in the class on the prevention and treatment of 
thromboembolism. 
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Introduction 
     Thromboembolic disease or venous thromboembolism (VTE) is an important public health 
problem. A total of two million Americans suffer from VTE each year; approximately 200,000 
deaths annually result from pulmonary embolism (PE) (Fekrazad et al. 2009). The morbidity 
associated with VTE often goes unrecognized.  The morbidity includes serious long term 
complications such as chronic edema, chronic venous insufficiency, chronic pain, and recurrent 
venous ulceration which are known as post-thrombotic syndrome (Kahn 2006). VTE is 
preventable in many instances.  Identifying patient populations at risk for VTE and implementing 
evidence-based guidelines can decrease the number of untoward effects of this disease (Passman, 
2010). 
      
Purpose 
     The purpose of the VTE guideline is to provide evidence-based information that assists in the 
identification of populations at risk for the disease as well as provide evidence- based 
interventions aimed at prophylaxis and prevention. Empowering nurses with the guideline would 
allow the nurse to take responsibility for assessing patients for VTE and provide appropriate 
prophylaxis.  This allows nurses to help reduce the number of VTE incidences and the associated 
consequences.  Nurses are in a crucial position to help improve orthopaedic outcomes in relation 
to thromboembolism of the patient by providing evidence-based care.     
Definition of Problem 
   Approximately 700,000 primary total hip and knee replacements are performed each year in 
the United States.  The number is expected to grow to over 3.5 million in 2030 (AAOS, 2011). 
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On average, about 2 to 3% of people undergoing total joint replacement would end up with a 
symptomatic DVT or PE (AAOS, 2011). The orthopaedic nurse needs competency in performing 
two critical procedures in detecting thromboembolism. First, educate patients on prevention of 
thromboembolism.  Second, identify signs and symptoms of thromboembolism for timely 
intervention.  
Goals of Clinical Practice Guideline 
     The goal for the guideline is the significance of addressing orthopaedic trauma and total joint 
patients in developing VTE.  Orthopaedic trauma and total joint patients are among the highest 
risk groups for developing VTE. The guidelines would provide evidence- based interventions 
aimed at decreasing VTE events. VTE is considered to be one of the most preventable causes of 
death in the hospital (Mitchota, 2007).  Typically hospitals adhere to the ACCP guidelines.  
However, the AAOS guidelines are more appropriate for orthopaedic patients. Therefore, it is 
important to educate orthopaedic nurses on the differences of these guidelines and the care 
needed for the orthopaedic patient.  
     During the last decade, the American College of Chest Physicians (ACCP) and the American 
Academy of Orthopaedic Surgeons (AAOS) developed their own guidelines for prevention of 
venous thromboembolism which were not in agreement which posed dilemmas for those 
managing the care of these patients. The guidelines were also not congruent with the guidelines 
set forth by the Surgical Care Improvement Project (SCIP). The SCIP is a national partnership 
that was developed in 2003 by the Centers for Medicare and Medicaid Services (CMS), and the 
Centers for Disease Control (CDC). Other SCIP steering committee organizations include the 
American College of Surgeons, the American Hospital Association, The Joint Commission, the 
American Society of Anesthesiologists, the Association of PeriOperative Registered Nurses 
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(AORN), the Agency for Healthcare Research and Quality, and the Department of Veterans 
Affairs. These organizations are committed to improving the safety of surgical care through the 
reduction of postoperative complications by utilizing evidence-based core measures (Drake, 
2011).  
Search Strategy 
     The following databases were searched: National Guidelines Clearinghouse, The Cochrane 
Library, PubMed, CINAHL, Medline, and Academic Search.  The search was limited to only 
articles written in English. No limits were placed when the articles were published. Only original 
studies were used form peer reviewed journals. The following key words were included in the 
search: pulmonary embolism; venous thromboembolism; deep vein thrombosis; and clinical 
guidelines. 
Assessment of Scientific Evidence 
     Prior to 2012, the ACCP and the AAOS independently published guidelines for prevention of 
VTE in the orthopaedic patient. These guidelines proposed very different approaches to 
managing these patients which caused confusion and wide variations in practice. The ACCP 8
th
 
Consensus guidelines were the most widely used in most clinical practices but often resulted in 
excessive bleeding (Bozic, Vail, Pekow et al., 2010). The differences in guidelines were as a 
result of each different organization using different endpoints for evaluating the efficacy of VTE 
prophylactic drugs. The ACCP used venographically proven DVT as its endpoint while the 
AAOS used excessive bleeding as its endpoint.  The problem with bleeding as an endpoint is that 
the ACCP defined major bleeding as life threatening intracranial, intraabdominal or intraocular 
bleeding and requiring at least two units of packed red cells or decrease of hemoglobin more than 
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2 g/dL compared with relevant postoperative level (Bozic, Vail, Pekow et al., 2010). Those 
criteria rarely apply to arthroplasty patients.  Galat et al (2009) reported that patients with wound 
complications of bleeding requiring reoperation within 30 days of TKA were 10 times more 
likely to have subsequent major surgery and associated morbidities than those without. However, 
failure to meet the ACCPs strict criteria of major bleeding event resulted in under reporting of 
bleeding complications in many studies. There were also concerns about conflicts of interest that 
appeared in the ACCP guidelines. 
     Due to the many concerns raised regarding the ACCP guidelines, the AAOS formed its 
DVT/PE workgroup in 2007 and issued its own revised recommendations in 2011 by reviewing 
the available literature on VTE with symptomatic DVT, PE, and mortality as endpoints (Mont et 
al., 2011).The goal was to achieve more balance between minimizing risk and maximizing 
efficacy, while minimizing conflicts of interest during the guideline development. Patients were 
classified based on their medical history to identify their risk of VTE and bleeding. The AAOS 
guidelines were in conflict with the ACCP guidelines until the ninth edition of the ACCP 
recommendations, which was published in 2012 (Falck-Yetter et al. as cited in Bozic, Vail, 
Pekow et al., 2010). Both of those guidelines, for the first time, included aspirin as an accepted 
therapeutic modality for the prevention of VTE.  
     The alignment of the major recommendations between the AAOS and the ACCP also are now 
aligned with the SCIP VTE guidelines.  
The SCIP VTE guidelines set forth include: 
* SCIP-VTE-1. This measure states that surgery patients will have recommended VTE 
prophylaxis ordered. VTE prophylaxis starts with identification of risk factors, including the 
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patient having surgery (higher risk with hip or knee surgery), trauma to lower extremities, 
increasing age (older than age 40), hormonal therapy, chemotherapy, central line catheter 
placement, immobility, obesity, varicose veins, and pregnancy (antepartum and postpartum). 
There are a number of risk assessments scoring tools available to assist in the determination of 
patient risk severity. Determining if the patient is at low, moderate, or high risk for VTE will 
guide the team to select the prophylactic treatment. As soon as a patient is admitted to the 
inpatient unit or is known to be staying more than 24 hours, a risk assessment needs to be 
completed. After the risk level is assigned, the appropriate intervention can be ordered and 
implemented. 
     Interventions are separated into two categories: nonpharmacologic and pharmacologic. The 
first intervention is frequent and early ambulation. The second nonpharmacologic intervention is 
the use of graduated compression stockings or intermittent pneumatic compression devices. 
Nurses need to know the importance of applying and using these devices for patients with 
limited mobility. Patients identified as moderate or high risk will also receive pharmacologic 
intervention of a low-dose unfractionated or low-molecular-weight heparin. 
* SCIP-VTE-2. This measure states that surgical patients will receive appropriate VTE 
prophylaxis within 24 hours before surgery to 24 hours after surgery. Again, the timing of post-
op medication administration is important. Organizations using best practice alerts may improve 
their outcomes by getting prophylaxis ordered and implemented early (Drake, 2011). 
     Although guidelines issued by the AAOS and the ACCP are valuable resources on the use of 
VTE prophylaxis, only the SCIP VTE prophylaxis measures are tied to CMS pay-for-
performance programs. Thus, hospitals must ensure that they conform to the SCIP measures for 
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VTE prophylaxis to qualify for bonus payments (McKee, 2013). This is critical information for 
the nurse caring for the high risk orthopaedic patient to know. 
Gaps in the Literature 
     There is considerable evidence in the literature that provides a vast array of treatment for 
thromboembolism, however there continues to remain a gap in the implementation of these 
treatments (Passman, 2010).    The guidelines have been vastly underused even with all of the 
supporting evidence.  One reason for the lack of implementation may be the lack of consensus 
among providers for the best treatment options.  The Surgical Care Improvement project (SCIP) 
was established as a collaborative effort between the Centers for Medicare and Medicaid 
Services (CMS) and the Joint Commission (Passman, 2010).  In 2010 the SCIP project included 
the Agency for Healthcare Research and Quality, American College of Surgeons, American 
Hospital Association, American Society of Anesthesiologists, Centers for Disease Control and 
Prevention, CMS, Department of Veterans Affairs, Institute for Healthcare Improvement, and the 
Joint Commission.  The focus of the SCIP project was to prevent surgery complications that have 
a relative high incidence and cost.  The SCIP program targeted VTE.  Haralson describes the 
four measures that relate to the SCIP guideline for VTE.   
     Thromboembolism has become a mandated quality of care, however the economic 
manifestations of this care have yet to be realized (Passman, 2010).   There continues to remain 
data that accurately assess the total economic burden for VTE.  The estimated total cost on the 
United Stated for VTE is $3.2 to $15.5 billion per year (Cundiff, 2004). In the United States 
there are as many as 900,000 that develop a DVT or a PE per year and as many as 300,000 
deaths are attributed to VTE per year (Heit, Cohen, & Anderson, 2005).  The AHRQ Healthcare 
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and Utilization Project estimated the cost for an inpatient to be $10,000 per DVT and $20,000 
per PE (Maynard & Stein, 2008).  Another study found direct patient cost for DVT to be $17,512 
and $18,310 for a PE (MacDougall et al. 2006).  Also, an estimated $18,310 can be added to 
hospital costs for added complications from a VTE (Dimick et al. 2004).  The patient that 
sustains a VTE not only has the acute hospital costs, but also chronic complication costs.  It is 
estimated that a patient that sustains a VTE has an incidence of 7-13% to have a recurrence 
within a year and a 30% recurrence within 5 years (Cushman et al. 2004).  
     Further research is needed to determine the most efficient translation of recommendations 
from research to the actual treatment of the patient.  Both the ACCP and AAOS agree that the 
most important goal is to prevent a pulmonary embolism.  The ACCP looks at both pulmonary 
embolism and deep vein thrombosis as a measurable outcome and the AAOS looks at only a 
pulmonary embolism as a measurable outcome. Therefore, the AAOS concentrates primarily on 
pulmonary embolism only and does not test routinely for deep vein thrombosis.  The ACCP 
includes both asymptomatic and symptomatic deep vein thrombosis detected by venography as a 
measure of the efficiency of thrombophylaxis in the prevention of VTE.  The AAOS rejects this 
and states that the link between DVT and VTE has not been proven (Eikelboom et al. 2009).  
The ACCP believes that the AAOS recommendations were based on experts rather than 
scientific research. The AAOS states that the ACCP fails to look at the increased bleeding risk 
associated with their recommendations (Knesk, Peterson, & Marke, 2012).  The increased 
bleeding risk associated with the post surgical patient may put the patient at increased infection 
risk.  
Pathophysiology 
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     Venous thrombosis is the formation of blood clots in low blood flow veins that are composed 
mainly of red blood cells trapped in a fibrin network.  In orthopaedic patients, clots frequently 
are seen in deep veins in the calf or thigh vessels. Clots tend to form at valve cusps in these 
veins. These clots are known as venous thrombosis. A pulmonary embolism (PE) is a clot that 
has broken free from the inner layer of the vein. The clot travels through the venous system and 
eventually migrates to the pulmonary venous circulation and blocks blood flow resulting in 
serious interruption in oxygen exchange at the alveolar-capillary membrane. If the clot is large 
enough to totally occlude the pulmonary vein, abrupt and often fatal right sided heart failure 
(called cor pulmonale) can occur (Patel & Brenner, 2014; Schwartz & Rote, 2014).  
     Virchow (Welsh, 2010) identified the triad of factors which contribute to clot formation.  The 
triad describes how venous stasis-alterations in blood flow can lead to sluggish circulation. This 
happens after surgery when immobile patients have a reduction in the contractions of muscles in 
the lower leg. The reduction in the contractions of the muscles leads to stagnant blood that can 
trigger endothelial wall damage and lead to thrombus formation (Welsh, 2010).  Vessel wall 
damage occurs by the kinking of major vessels (hip dislocation), trauma, indwelling catheters, or 
scarring by previous clots.  Endothelial damage to the vein wall can occur which can activate the 
clotting cascade leading to increased thrombosis (Coleridge-Smith, 1990). 
     Blood coagulabilty in the process of clot formation can be due to inherited disorders (Factor 
V Leiden, protein C or S deficiency), cancer, estrogen therapies and major surgery.  Patients that 
have congenital thrombophilia generally remain asymptomatic until their clotting disorder faces 
a challenge such as surgery (Mammen, 1992).  It is often a combination of factors which leads to 
clot formation. 
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     Orthopaedic patients are at risk for all three factors of Virchow triad in the perioperative 
period:  changes in blood coagulation, changes in the vessel wall, and changes in blood flow.  In 
addition the following risk factors put the orthopaedic patient at risk: surgery; trauma, especially 
to the lower extremities; immobility; malignancy; history of DVT; older age; pregnancy or 
postpartum period; taking estrogen-containing oral contraceptives; inflammatory bowel disease; 
obesity; smoking; and varicose veins (Geerts et al. 2008). 
Patient Care Management 
      A multi-modal approach to VTE prevention is the accepted standard of care with orthopaedic 
joint replacement and hip fracture patients. The ACCP (2012) recommends a combination of 
pharmacologic and mechanical thromboprophylaxis for patients undergoing major orthopaedic 
surgery such as total hip arthroplasty (THA), total knee arthroplasty (TKA), and hip fracture 
surgery (HFS).  The use of dual therapy with pharmacologic and mechanical prophylaxis was 
found to be superior to no prophylaxis.  For patients undergoing a THA or a TKA the use of an 
intermittent pneumatic compression device (IPCD) is recommended with one of the following 
pharmacologic measures for a minimum of 10 to 14 days- low-molecular-weight heparin 
(LMWH), fondaparinux, apixaban, dabigatran, rivaroxaban, low-dose unfractionated heparin 
(LDUH), warfarin therapy, or aspirin.  For patients undergoing HFS, the recommendation is to 
use an IPCD with one of the following for a minimum of 10 to 14 days; LMWH, fondaparinux, 
LDUH, adjusted-dose VKA, or aspirin. Though the minimum recommendation for the length of 
treatment is 10-14 days it is also the recommendation of ACCP to extend the 
thromboprophylaxis in the outpatient period for up to 35 days from the day of surgery. 
Additionally, though ACCP supports the use of the above listed pharmacologic prophylaxis 
options for THA, TKA, and HFS patients the recommended preference for pharmacologic 
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prophylaxis is LMWH. For patients receiving LMWH as thromboprophylaxis the 
recommendation is to start the medication either 12 hours or more preoperatively or 12 hours or 
more postoperatively rather than within 4 hours or less preoperatively or 4 hours or less 
postoperatively.   
      Thromboprophylaxis increases the risk for bleeding.  If patients are at an increased risk for 
bleeding the recommendation is to use an IPCD or no prophylaxis.  When patients decline 
treatments or are unable or unwilling to do injections or use IPCDs it is recommended to use 
apixaban or dabigatran (alternatively rivaroxaban or adjusted-dose VKA if apixaban or 
dabigatran are unavailable).  When there are contraindications to both pharmacologic and 
mechanical thromboprophylaxis the patient is at risk for increased risk of bleeding, the 
recommendation is against the use an inferior vena cava (IVC) filter placement for primary 
prevention. 
     The AAOS (2011) recommend against routine post-operative duplex ultrasonography 
screening of patients who have undergone elective THA or TKA.  Patients undergoing elective 
THA or TKA are already at an increased risk of VTE As these patients are already at an 
increased the recommendation is to identify and assess those patients at a higher risk for VTE 
development. The practitioner should evaluate the patient and determine whether these patients 
have a history of venous thromboembolism.  Patients undergoing elective THA or TKA 
which/who are at risk for bleeding and bleeding-associated complications should be assessed for 
known bleeding disorders like hemophilia and presence of active liver disease which further 
increase the risk for bleeding and bleeding-associated complications. 
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     Another recommendation is that patients should discontinue antiplatelet agents (e.g., aspirin, 
clopidogrel) before undergoing elective THA or TKA.  The use of pharmacologic agents and/or 
mechanical compressive devices for the prevention of VTE disease in patients undergoing 
elective THA or TKA is dependent on the patient’s risk.  For patients not at elevated risk of 
VTE, beyond that of the surgery, the recommendation is to use pharmacologic agents and/or 
mechanical compressive devices.  For patients who have had a previous VTE, the 
recommendation is to use pharmacologic prophylaxis and mechanical compressive devices.  
Though there is not strong evidence, patients undergoing elective THA or TKA and who have a 
known bleeding disorder (e.g., hemophilia) and/or active liver disease, the recommendation are 
to use mechanical compressive devices for preventing VTE.  Additionally, early mobilization 
following THA or TKA is recommended.  Early mobilization is of low cost, minimal risk to the 
patient, and consistent with current practice.  Neuraxial anesthesia (such as intrathecal, epidural, 
and spinal) was recommended for patients undergoing elective THA or TKA. Neuraxial blocks 
have been shown to have no effect on the evidence of VTE and may also help to limit blood loss 
during surgery.  The use of an inferior Vena Cava (IVC) filter was not recommended for or 
against. 
Assessment 
      All patients should be assessed pre-operatively for elevated risk of VTE.  A written 
thromboprophylaxis policy should be in place for the institution along with preprinted orders, 
periodic audit, and feedback.   
     The physical exam for DVT includes    
 pain and tenderness at or below the site of the thrombosis; 
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 swelling of the affected leg; 
 elevating the leg may lessen the swelling, however, the swelling returns with ambulation;  
 pitting edema confined to the symptomatic leg;  
 redness of the affected extremity; and 
 homan’s sign (forced dorsiflexion of the foot causing discomfort in the calf) is present in 
less than one third of the patients and not specific or sensitive for DVT   
The physical exam should be documented in the pre assessment nursing notes prior to surgery.    
Current mainstay for determining DVT probability is the Wells Score. 
 Risk score interpretation (probability of DVT): 3 points: high risk (75%); 1 to 
2 points: moderate risk (17%); < 1 point: low risk (3%). 
 
Active cancer? 
 
+1 
 
Bedridden recently >3 days or major surgery within four weeks? 
 
+1 
 
Calf swelling >3cm compared to the other leg? 
 
+1 
 
Collateral (nonvaricose) superficial veins present? 
 
+1 
 
Entire leg swollen? 
 
+1 
 
Localized tenderness along the deep venous system? 
 
+1 
 
Pitting edema, greater in the symptomatic leg? 
 
+1 
 
Paralysis, paresis, or recent plaster immobilization of the lower extremity 
 
+1 
 
Previously documented DVT? 
 
+1 
 
Alternative diagnosis to DVT as likely or more likely? 
 
-2 
(Adapted from Duggar, 2014) 
 
     The physical exam for PE includes   
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 severe dyspnea;   
 chest pain; 
 hypoxia; 
 apprehension; 
 confusion; 
 anxiety; 
 Tachypenia;  
 Tachycardia; 
 diminished breath sounds;  
 fever; 
 diaphoresis;  
 hemoptysis; 
 pleuritic chest pain; and  
 a Split S2 may be heard which is a systolic murmur over the pulmonary artery due to an 
obstruction. 
The physical exam for the PE should be documented in the pre assessment nursing notes prior to 
surgery. 
     The medical management of DVT includes physical measures, mechanical prophylaxis, and 
pharmacological agents with contraindications.  Physical measures of DVT include:  
 Patients are to be out of bed, sitting in a chair several times a day, and ambulating as 
tolerated. 
 Elevate the foot of the bed. and 
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 Patients to be instructed to actively dorsiflex and plantar flex the ankle and toes. This 
exercise should be performed in sets of 10 to 20 every half hour when the patient is 
awake. 
     Mechanical prophylaxis for DVT assists with the venous return in patients and can be 
intermittent external pneumatic compression (IPC) or anti-embolism stockings (AES).  
Intermittent external pneumatic compression (IPC) provides external compression of the lower 
extremities, promoting venous return.  Contraindications of IPC includes 
 a known or suspected DVT; 
 local leg conditions; 
 arteriosclerosis vascular disease or neuropathy;  
 massive edema of legs or pulmonary edema; 
 extreme deformity of the legs; and 
 patient refusal to wear correctly (Welch, 2010).    
     Anti-embolism stockings (AES) provide continuous stimulation of linear blood flow, prevent 
venous dilation (Coleridge-Smith et al., 1991), and stimulate endothelial fibrinolytic activity 
(Arcelus et al., 1995). Contraindications of AES includes 
 local leg conditions; 
 arteriosclerosis vascular disease or neuropathy;  
 massive edema of legs or pulmonary edema; 
 extreme deformity of the legs; 
 allergy to material; and 
 patient refusal to wear correctly (Welch, 2010). 
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Multiple pharmacologic agents can be used with thromboembolism.  It is important to start 
treatment with parenteral anticoagulation for DVT or PE while awaiting diagnostic test results 
unless low clinical suspicion of VTE (LMWH or fondaparinux recommended over heparin). 
Continue treatment at home if circumstances allow.  If contraindications for pharmacologic 
therapy, the use of mobile IPC is recommended as long as there is a chip that can be interrogated 
to check for compliance.   
     Therapy length is based on underlying risk factor.  Post-operative patient is 3 months.  
Provoked non-surgical with transient risk is 3 months (assuming that risk factor is resolved). 
Unprovoked proximal is 3 months, then reevaluate for risk-benefit (may stop if high bleeding 
risk, otherwise extended therapy is recommended).  Unprovoked isolated distal DVT is 3 
months.  Second
 
unprovoked VTE needs extended therapy.  Therapy is only 3 months for 
patients at a high bleeding risk.  Active cancer needs extended therapy. Reassess extended 
therapy patients for continued treatment at periodic intervals. 
     Unfractionated heparin works by Heparin-activation of antithrombin III that inactivates 
thrombin and factor Xa in the coagulation process.  Unfractionated heparin requires monitoring 
with the goal of maintaining an elevated activated partial thromboplastin time (APTT) (Knesek et 
al., 2012).  Heparin is given in a bolus of 80units/kg or fixed 5000 units. Continuous infusion at 
18units/kg/hr or fixed 1000 units/hr is maintained.  Outpatient therapy is 333 units/kg as the first 
dose, then 250 units/kg (no aPPT monitoring recommended). 
     Warfarin-affects prothrombin time by competing with vitamin K. Warfarin is given as 10mg 
daily for 2 days, then dose per INR for sufficiently healthy patients, otherwise start with 5 mg 
daily.  Start warfarin on day 1 or 2. Once the patient is stabilized on a specific dose, INR 
measurements are done at 1 to 2 week intervals (Knesek et al., 2012).   
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     Low molecular weight heparin (LMWH) is administered via the subcutaneous route with 
daily or twice daily dosing without coagulation monitoring.  LMWH reduces 
hypercoagulability by inhibiting coagulation proteins through increased antithrombin action 
(Knesek et al., 2012).  Use LMWH over dabigatran or rivaroxaban if unable to take warfarin 
(lack of data when 2012 CHEST guidelines published).  Use LMWH over warfarin in cancer 
patients for long term treatment. 
     Factor Xa inhibitors-Rivaraxaban (Xarelto) should be taken orally once daily in 10-mg doses. 
The initial dose should be taken 6 to 10 hours after surgery, provided that hemostasis has been 
established. Recommended treatment durations are 4 weeks for patients having major hip 
surgery and 2 weeks for patients having major knee surgery (Eymin & Jaffer, 2013).   
 Discontinue injectable anticoagulation when starting rivaroxaban. Factor Xa inhibitor 
Fondaparinux (Arixtra) is a synthetic polysaccharide derived from the antithrombin-binding 
region of heparin. Fondaparinux is administered via the subcutaneous route once daily 
(Yamaguchi et al., 2010).   
     Aspirin inhibits the production of thromboxane creating an antiplatelet effect (Autar, 2006).   
The AAOS recommends the use of ASA for patients with no history of malignancy, no previous 
clots, and no history of thrombophilia for the prevention of VTE (Knesek et al., 2012). Optimal 
dose is 160 mg by mouth every day. 
     Contraindications of pharmacological prophylaxis includes 
 active bleeding; 
 bleeding disorders such as liver failure and hemophilia;  
 concurrent use of anticoagulants; 
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 lumbar puncture, epidural or spinal anesthesia within the previous 4 hours, or expected 
within the next 12 hours; 
 acute stroke; 
 platelets less than 75 x 109/l; and  
 hypertension (230/120 mmHg or more) (Welch, 2010). 
     Treatment of DVT includes anticoagulation for 3 months, noninvasive tests for 10 to 14 days, 
or surgery. 
     Management of PE can be done with medication or surgery. The anticoagulation medication 
can be Heparin, LMWH, or Warfarin.  Thrombolytic therapy is used with massive PE in 
combination with heparin. Agents used include:  streptokinase, urokinase, and recombinant 
tissue-type plasminogen. Surgical and invasive procedures can be an IVC filter, prophylactic 
IVC filter, pulmonary embolectomy, and or supplemental oxygen.  Contraindications of 
pharmacological prophylaxis includes 
 active bleeding;  
 bleeding disorders such as liver failure and hemophilia;  
 concurrent use of anticoagulants; 
 lumbar puncture, epidural or spinal anesthesia within the previous 4 hours, or expected 
within the next 12 hours; 
 acute stroke; 
 platelets less than 75 x 109/l; and  
 severe hypertension (230/120 mmHg or more) (Welch, 2010). 
     There are certain pregnancy and lactations considerations 
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 LMWH preferred over unfractionated heparin;  
 Warfarin is contraindicated (able to be used in breastfeeding); 
 Patients on warfarin should be changed to therapeutic LMWH when positive; 
 Avoid fondaparinux or parenteral direct thrombin inhibitors; 
 Avoid oral dabigatran and rivaroxaban or similar agents; 
 Continue acute VTE treatment for at least 6 weeks postpartum for minimum of total 
therapy of 3 months; and 
 Discontinue therapeutic LMWH at least 24 hours before labor injection or neuraxial 
anesthesia 
     There are a number of diagnostic tests for DVT.  One test is the venous ultrasonography 
which is a noninvasive sensitive and accurate test to locate a thrombus in the deep and superficial 
venous system. Another test is the venous doppler which is a noninvasive continuous wave 
doppler used to evaluate venous flow patter.  Sensitive to proximal vein thrombosis; however, it 
has poor sensitivity to calf vein thrombosis. The gold standard test is a Venography which is the 
use of dye injected into a vein to assess for a thrombosis (Maher, Salmond, & Pellino 2002). 
     Also, a lab test called a D-dimer may be used for a diagnostic test in evaluating for a DVT.  A 
D-dimer is a lab test showing protein derivatives of fibrin found in plasma. Plasma 
concentrations are raised during a thromboembolism, infection, malignancy, pregnancy, and after 
an operation. A negative test can rule out a VTE. 
     There are a number of tests used in the diagnosing and managing a PE.  The diagnostic tests 
and management tests for a PE include the following:  
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 Ventilation/Perfusion scan which is a less invasive test that uses x-ray and dye to assess 
ventilation and pulmonary perfusion. 
 Pulmonary angiography which is an invasive test that uses a catheter inserted into the 
pulmonary artery for the injection of dye. 
 Spiral test computed tomography scanning which is a noninvasive test that uses x-ray to 
show pulmonary vasculature and parenchyma. 
 D-dimer which is a lab test showing protein derivatives of fibrin found in plasma. Plasma 
concentrations are raised during a thromboembolism, infection, malignancy, pregnancy, 
and after an operation.  
 Arterial blood gas which is a lab test used to show hypoxia.  
 Electrocardiogram (ECG) which may show nonspecific ST and T-wave changes.  This 
test is not used to make a diagnosis of PE, however; is used in the management of PE.  
 Echocardiogram is used to evaluate for intracardiac clot. and 
 Chest radiography is not conclusive for a PE, however; it may show effusion, infiltrate, 
atelectasis, elevated hemidiaphragm, and be used to rule out other conditions (Maher, 
Salmon, & Pellino, 2002). 
     There are risk identification factors for DVT and PE.  The risk identification factors fall into 
three categories.  They are inherited, acquired, and additional risk factors.  The inherited risk 
factors includes 
 antithrombin III deficiency; 
 Protein C deficiency; 
 Protein S deficiency; 
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 Dysfibrinogenemia; 
 disorders of plasminogen and plasminogen activation;  
 Factor V; and 
 Von Willebrand disease    
     The acquired risk factors includes    
 lupus anticoagulant;  
 nephrotic syndrome; 
 paroxysmal nocturnal hemoglobinuria;  
 cancer; 
 malignancy;  
 stasis (cardiac heart failure, myocardial infarction, cardiomyopathy, constrictive 
pericarditis, anasarca);  
 sepsis; 
 immobilization;  
 stroke; 
 polycythemia rubra vera;  
 inflammatory bowel disease;  
 obesity; and 
 prior thromboembolism (Maher, Salmond, & Pellino, 2002).    
     The additional risk factors are 
 surgery;  
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 trauma-especially to the lower extremities;  
 immobility; 
 history of DVT;  
 advancing  age; 
 pregnancy or postpartum;  
 estrogen therapy or taking estrogen-containing oral contraceptives; 
 smoking; and 
 varicose veins (Geerts et al. 2006). 
     Nursing interventions need to be a part of the management of DVT and PE.  The nursing 
diagnosis is made and nursing interventions along with nursing outcomes are used in the care 
and treatment of the patient.   
Nursing Interventions are included in the following table: 
Nursing Diagnosis 
(NANDA) 
Nurisng Intervention Classification 
(NIC) 
Nursing Outcome 
Classification NOC) 
Anxiety Active listening, anticipatory 
guidance, anxiety reduction, calming 
techniques, coping enhancement, 
emotional support, presence, relation 
therapy. 
 
Anxiety self-control 
Concentration 
Coping 
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Gas exchange, 
impaired 
Airway management, cough 
enhancement, embolus care, laboratory 
data interpretation, oxygen therapy, 
respiratory monitoring. 
 
Respiratory status:  gas 
exchange 
Respiratory status:  
ventilation 
Tissue perfusion  
Vital signs  
Knowledge deficit Risk identification, disease process, 
teaching, prescribed medications, 
procedures and treatments 
Knowledge:  medication 
Knowledge: pain 
management 
Knowledge: prescribed 
activity 
Knowledge: treatment 
procedures 
Knowledge:  treatment 
regimen 
Mobility:  physical, 
impaired 
Analgesic administration, bed rest 
care, body mechanics promotion, 
exercise promotion (strength training), 
exercise promotion, fall prevention, 
Ambulation 
Body mechanics 
Body positioning: self-
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pain management, self-care assistance, 
teaching (prescribed activity/exercise) 
initiated 
Client satisfaction: 
functional assistance 
Mobility 
Transfer performance 
Pain, acute Analgesic administration, coping 
enhancement, environmental 
management (comfort), pain 
management, positioning, simple 
guided imagery, simple message, 
simple relaxation techniques, teaching 
(prescribed medication) 
Client satisfaction:  pain 
management 
Discomfort level 
Medication response 
Pain control 
Pain level 
Peripheral 
neurovascular 
dysfunction, risk for 
Bed rest care, embolus precautions, 
neurologic monitoring, pressure 
management 
Circulation status 
Neurological status: 
peripheral 
Tissue perfusion:  
peripheral 
Tissue Perfusion, 
peripheral, 
Promotion of arterial circulation, 
circulatory care (venous 
Circulation status 
Fluid overload severity 
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ineffective insufficiency), circulatory precautions, 
fluid/electrolyte management, fluid 
management, hemodynamic 
regulation, hypervolemia management, 
neurologic monitoring 
 
Tissue integrity: skin 
and mucous membranes 
Tissue perfusion:  
peripheral 
 
     Education is an important nursing consideration for patients and family in the management of 
DVT and PE.  Patient education on signs and symptoms of DVT & PE as well as risk of bleeding 
while taking anticoagulants should be addressed.   
     DVT education should include the the patient will have pain tenderness over area of clot, 
swelling of the thigh, tightness of the calf, and discoloration of the skin.  PE education should 
include that the pt may experience 
 dyspnea;  
 anxiety; 
 restlessness;  
 increased respirations;  
 cough, hemoptysis;  
 tachycardia; 
 syncope; and 
 diaphoresis.   
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     Patient education for prevention with lifestyle changes for DVT and PE includes  
 smoking cessation; 
 weight loss; 
 blood pressure control;  
 avoid prolong sitting or standing;  
 frequent exercises of lower calf muscles; and 
 use of compression stockings as directed.   
     Patient education on medication for DVT and PE should include that the patient should not 
take any over-the-counter medications, supplements, or herbal remedies before telling the 
provider.  Protect self from injury. Take the anticoagulant at the same time every day.  If a dose 
is missed take as soon as possible unless it is time for next dose. If it is time for next dose do not 
take a double dose just take the regular dose for the day.  Have blood tests as often as directed.  
Tell any healthcare provider seen for care (such as doctors, dentists, chiropractors, and home 
health nurses) about taking an anticoagulant.  Use a soft-bristled toothbrush. Use an electric razor 
to shave.  Many foods contain vitamin K, which helps blood clot. Foods high in vitamin K may 
include asparagus, avocado, broccoli, and cabbage. Do not change the amount of these foods 
usually ingested.  Do not drink alcohol.  Report any of the following: nausea; diarrhea; poor 
appetite; bleeding that doesn’t stop in 10 minutes; coughing or throwing up blood; dark-colored 
urine or black stools; red or black-and-blue marks on the skin; dizziness or fatigue; and chest 
pain or trouble breathing. 
     Education of the patient and family members regarding signs and symptoms of DVT, the 
prophylaxis protocol being used, and the importance of early ambulation needs to be included in 
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the nursing education.  The delivery of the education should be verbally and in written form.  If 
the patient is unable to understand the information, provide the information to the caregiver.        
Discharge education should include   
 means of preventing a DVT;  
 importance of early ambulation;  
 benefits of prescribed prophylaxis;  
 signs and symptoms of DVT and PE;  
 generic and trade names of all medications prescribed;  
 early ways to recognize complications of treatment; and  
 any medical contact numbers.   
     The discharge destination for the patient is based on the level of skilled care needed by the 
patient and the functional status of the patient at discharge. The optimal destination would be the 
patient’s home with full return to functional status. Assistance may be needed for skilled care 
and rehabilitation at a skilled facility, which should be established prior to discharge. 
Trends and Controversies 
     Developments of the new oral anticoagulants’ positive effects include efficacy, predictability 
and consistency, clinical monitoring, adherence to use and duration, and convenience. Negative 
effects include issues of bleeding complications, liver enzyme elevation, influence on renal 
disease, drug-to-drug interactions, no antidote to reverse bleeding, and no reliable assay to 
measure effects (Nutescu et al., 2005). 
     Cost consideration needs to be taken into account with any new treatment modality.  A cost 
effectiveness analysis should be performed to include reviewing improved effectiveness, greater 
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efficacy, and reduced complications.  VTE continues to remain a significant concern.  Use of 
automated computer prompts and admission protocols may lead to using more routine 
prophylaxis.  It will take all health care providers, patients, and hospitals working as a team to 
ensure adequate prophylactic treatment for DVT. 
 
Project Description/Theory 
     The project was developed with the intent to develop a clinical guideline for nurses on the 
prevention of thromboembolism in the orthopaedic patient.  The final project will be presented to 
the National Association of Orthopaedic Nurses for review and publication.  The strength of the 
project will calculated from a pre and post test on thromboembolism that will be presented to a 
group of nurses at Selby General Hospital in Marietta Ohio studying for the national orthopaedic 
certification test. 
     The Knowles (1998) learning theory will be used in teaching the thromboembolism guideline. 
The theory has six principles of learning.  Knowles identified six principles. The first principle is 
the need to know.  Adults need to know why they should learn, the reason to learn, and how it 
will benefit them. The nurses participating in the orthopaedic class need to learn what will be on 
the certification test and what areas they need to further study.  This will help them in completing 
their certification as an orthopaedic nurse.  The second principle is self-concept.  Adults need to 
be moved into a self-directed learner where they are responsible for their own learning and the 
direction it takes. The nurses will need to evaluate their own knowledge to stimulate themselves 
to study on their own.  The third principle is the role of experience.  An adult’s experience 
should be used in their new learning and the technique should include ways to include the adult’s 
knowledge as a tool that they can draw upon from their experiences. The nurses will draw upon 
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their past experience and education to aid them in providing evidence based-care and in studying 
for the certification test.  The fourth principle is readiness to learn.  The nurses signed up for the 
class are already expressing their readiness to learn.  The fifth principle is orientation to learning.  
New learning should clearly define how it will apply to life. The class will help each nurse in 
providing confident and competent care to the orthopaedic patient.  The sixth principle is 
motivation to learn.  Internal motivators are more important than the external motivators that 
adults may receive for more learning. These internal motivators can come in the form of 
increased job satisfaction, self-esteem, and quality of life. All of the nurses can take away a 
higher sense of self-esteem expanding their current knowledge and providing a well educated 
service to the nursing profession. 
     Knowles (1975) suggests the following:  learners who take the initiative learn more and 
better; enter into learning more purposefully and with greater motivation; and tend to retain 
better and longer.  The nurses in the orthopaedic class are volunteering their time to learn more 
about their profession.  They want to further their education by obtaining certification in their 
field and advance their professionalism.   
Capstone Project Design 
     The capstone project began with a pretest to be given to a class of orthopaedic nurses prior to 
an education course.  After the course the same test was administered again to see if there was a 
change in the initial score.   The course consisted of classes that span over a five week time 
period.  The nurses for the course came from the Mid-Ohio Valley and were employed at Selby 
General Hospital in Marietta Ohio.  The nurses took the class to prepare them for the National 
Association of Orthopaedic exam to become certified as an orthopaedic nurse.  A copy of the 
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course is listed in Appendix B.  There were three objectives identified for the course.  The first 
objective was for the participating nurses to complete the Orthopaedic Nurse Exam (ONC).  The 
ONC exam is based on an analysis of the practice of thousands of orthopaedic nurses across the 
United States. The second objective was to encourage self study for the ONC exam. This 
includes identifying a list of topics needed to cover during the individual course of study.  
Encourage a collection of professional resources to use as study aids including the national 
association of nurses online store.   The third objective was to establish a basic foundation for the 
use of evidence-based practice (EBP) in nursing.  EBP is a thoughtful integration of the best 
available evidence, coupled with clinical expertise that enables nurses to address healthcare 
questions with an evaluative and qualitative approach. EBP allows the nurse to assess current 
and past research, clinical guidelines, and other information resources in order to identify 
relevant literature while differentiating between high-quality and low-quality findings. To 
implement the understanding that EBP nursing consists of the following: formulating a well-built 
question; identifying articles and other evidence-based resources that answer the question; 
critically appraising the evidence to assess its validity; apply the evidence; and re-evaluate the 
application of evidence and areas for improvement.  The exact content of the classes are 
explained in Appendix B.  During week three the pre and post test was given for the capstone 
project.  A copy of the test is listed in Appendix A. 
      The capstone project clinical guideline was submitted to the National Association of 
Orthopaedic (NAON) executive board for review.  Recommendations from the executive board 
were given and the paper returned for any changes.  It was revised and returned to the executive 
board for placement on the NAON website for suggestions from other orthopaedic certified 
nurses. From this point all suggestions was considered and rewrites performed.  It was then 
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submitted for publication to the Orthopaedic Nursing Journal.  This submission was part of the 
Evidence Based Practice and Research committee.  The purpose of the committee was to 
promote and facilitate orthopaedic nursing practice and research initiatives to meet the needs and 
desires of NAON members and other orthopaedic health care providers. The scope of the 
committee was to develop, implement, and evaluate strategies for enhancing evidence-based 
orthopaedic nursing practice and research activities and tools.  This clinical pathway was one of 
four pathways that the committee is developing.   
Project Evaluation 
     Evaluation of the project was the improvement of scores on the post test after the instructional 
course of the class.  The ultimate final evaluation was the implementation of the clinical 
guideline by the National Association of Orthopaedic Nurses (NAON).  The clinical guideline 
went through a rigorous panel of experts for evaluation and rewrites and was approved for final 
publication onto the web based site and in the journal.  The panel consisted of active certified 
orthopaedic registered nurses and NAON members.  The members had least a baccalaureate 
degree and had recent practice experience within the specialty of orthopaedic nursing and/or 
familiarity with healthcare research.  
Results of the Project 
     Twenty-three registered nurses took the class and consented to participate with the pre test 
and posttest on thromboembolism. The results of all twenty-three participants are demonstrated 
in the following graph displaying the pretest and the posttest. 
 The data was as follows: 
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Participant Pretest Postest 
1 72 90 
2 80 94 
3 84 98 
4 60 98 
5 78 100 
6 90 100 
7 62 98 
8 60 94 
9 70 98 
10 72 96 
11 80 98 
12 84 100 
13 62 96 
14 78 98 
15 78 98 
16 60 100 
17 68 98 
18 74 100 
19 80 98 
20 84 100 
21 70 94 
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22 78 98 
23 74 94 
 
  Group   pretest     posttest   
Mean 73.83 97.45 
SD 8.74 2.56 
SEM 1.82 0.55 
N 23     23     
 
   
     Graph pad software (2014) was used to calculate the results.  A paired t test with one tail was 
used to calculate the results.  The P value and statistical difference was as follows: The two-
tailed P value is less than 0.0001. 
     By conventional criteria, this difference is considered to be extremely statistically significant.  
The confidence level was as follows:   The mean of pretest minus posttest equals -23.64 
  95% confidence interval of this difference: From -27.42 to -19.85.  Intermediate values used in 
calculations: t=12.9753, df=21, standard error of difference=1.822 
     From the above results it was demonstrated that the class did increase their knowledge from 
the pre and post test on the management and treatment of thromboembolism.   
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Discussion 
     The morbidity associated with venous thromboembolism often goes unrecognized and is 
preventable in many instances.  Identifying patient populations at risk for venous 
thromboembolism and implementing evidence-based guidelines can decrease the number of 
untoward effects of this disease.  Clinical pathway guidelines are valuable tools needed by nurses 
in the prevention and treatment of disorders for patients.  A clinical pathway guideline on 
thromboembolism is a valuable tool in for the orthopaedic nurse.  Education of the guideline can 
increase knowledge and understanding of what prevention, interventions, and treatment are 
available for the orthopaedic patient and how to apply this knowledge to everyday patient care.  
Competency in identifying signs and symptoms of thromboembolism and in education of 
patients and family on prevention of thromboembolism empowers the orthopaedic nurse to give 
the highest quality care to the orthopaedic patient. 
     This clinical practice guideline provides as an educational tool based on an assessment of 
current scientific and clinical research information.  This tool is not intended to replace a 
clinician’s independent judgment and critical thinking, but to enhance the clinician’s knowledge 
base regarding the detection and prevention of venous thromboembolism in the orthopaedic 
patient. The purposes of the venous thromboembolism guideline is to empower the nurse with 
the best evidence-based information to assist  in the identification of populations at risk for 
thromboembolism and provide the best care available in the treatment and prevention of 
thromboembolism. 
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Appendix A 
Pre-Test Examination for Thromboembolism 
Translating Evidence Based Research on Venous 
Thromboembolism into Practice 
Purpose/Goal 
To educate orthopaedic nurses about evidence-based practice to improve outcomes for 
orthopaedic surgical patients at risk for thromboembolism. 
Objectives 
After instructional course on evidence-based practice and VTE the orthopaedic nurse will be able 
to: 
1. Explain how evidence-based practice can improve patient outcomes with VTE 
2. Define VTE 
3. Describe the vascular pathophysiology that results in deep vein thrombosis and 
pulmonary embolism 
4. Discuss the effects of VTE 
5. Describe why surgical patients are at an increased risk for developing VTE 
6. Compare prevention and treatment options for VTE 
 
Questions 
1. The components of Virchow’s traid include venous stasis, vessel wall damage, and 
a. vessel length 
b. coagulation treatment 
c. coagulation changes 
d. vessel repair 
 
2.  Which of the following is a symptom or symptoms of a deep vein thrombosis? 
a. warmth to the area 
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b. localized tenderness or pain 
c. localized skin redness 
d. all of the above 
3.  Venous thromboembolism consists of which of the following? 
a. deep vein thrombosis 
 b. pulmonary embolism 
c. a only  
d. a & b 
4.  Which of the following is the most deadly complication of a deep vein thrombosis? 
a. atherosclerosis 
b. pulmonary embolism 
c. vascular rupture 
d. infection 
5.  Factors that predispose orthopaedic surgical patients to the development of a VTE 
include: 
a. dehydration 
b. immobility 
c. b only 
d. a & b 
6.  Nurses should encourage patients to: 
a. mobilize early  
b. perform breathing exercises 
c. a only 
d. a & b 
7.  The primary complication of intermittent pneumatic devices is 
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a. noncompliance 
b. delayed ambulation 
c. a only 
d. a & b 
8.  Symptom or symptoms of a pulmonary embolism are which of the following? 
a. unexplained shortness of breath 
b. tachycardia 
c. nervousness 
d. all of the above 
9. Adverse reaction or reactions to heparin include which of the following? 
a. hematoma 
b. compartment syndrome 
c. thrombocytopenia 
d. all of the above 
10.  The prevalence of VTE is increasing due to which of the following? 
a. aging of the population 
b. more complicated surgeries 
c. longer survival of patients with predisposing conditions  
d. all of the above 
 
 
 
 
   
 
Clinical Practice Guideline                                                                                                                                          
46 
 
 
Appendix B 
Orthopaedic Course Selby Hospital 
Angela Miller MSN, ONP-C, FNP-BC 
Purpose/Goal 
To provide an instructional course to orthopaedic nurses interested in completing the national 
orthopaedic certification exam.  This course will help to improve orthopaedic nursing knowledge 
while encouraging the practice of critical thinking skills in the implementation of evidence-based 
practice. 
Objectives 
1. To complete the Orthopaedic Nurse Exam upon finishing this course.  The ONC exam is 
based on an analysis of the practice of thousands of orthopaedic nurses across the United 
States. From that analysis, a test blueprint is constructed to determine what percentage of 
questions will cover each area of practice (content areas) and each nursing role (test 
objectives).The ONC examination contains 150 questions.  Of these, 135 are scored; the 
remaining 15 questions are pilot items, and the candidate’s performance on those questions 
will not be reflected in the exam score.  A raw score of 97 is needed to pass the examination, 
equaling 72% 
2. To encourage self study for the ONC exam. This includes identifying a list of topics needed 
to cover during the individual course of study.  Encourage a collection of professional 
resources to use as study aids including the national association of nurses on line store.  
3. To establish a basic foundation for the use of evidence-based practice (EBP) in nursing.  
EBP is a thoughtful integration of the best available evidence, coupled with clinical 
expertise that enables nurses to address healthcare questions with an evaluative and 
qualitative approach. EBP allows the nurse to assess current and past research, clinical 
guidelines, and other information resources in order to identify relevant literature while 
differentiating between high-quality and low-quality findings. To implement the 
understanding that EBP nursing consists of the following: formulating a well-built 
question; identifying articles and other evidence-based resources that answer the question; 
critically appraising the evidence to assess its validity; apply the evidence; and re-evaluate 
the application of evidence and areas for improvement. 
Course Instruction 
Week 1:  Degenerative Joint Disease                                               2 hours 
 Osteoarthritis 
 Charcot joints 
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 Chondromalacia of the patella 
 Posttraumatic arthritis 
 Hallux valgus 
Week 2:  Test on Degenerative Joint Disease                                      30 minutes                           
                                                                                                                               
 Inflammatory Disease                                                                          30 minutes    
 Rheumatoid arthritis 
 Systemic lupus erythematosus 
 Psoriatic arthritis 
 Systemic sclerosis 
 Ankylosing spondylitis 
 Bursitis  
 fibromyalgia 
Metabolic Bone Disease                                                                         30 minutes 
 Osteoporosis 
 Paget’s disease 
 Gout 
 Avascular necrosis 
Neuromuscular /Pediatric/Congenital                                                     30 minutes  
 Osteogenesis imperfect 
 Slipped capital femoral epiphysis 
 Osgood-Schlatter disease 
 Tibial torsion 
 Spina bifida 
Week 3:  Test on Inflammatory Disease, Metabolic Bone Disease, and Neuromuscular/ 
Pediatric/Congenital                                                                               30 minutes 
Oncology:  Musculoskeletal Tumors                                                      30 minutes 
 Osteosarcoma 
 Ewing’s sarcoma 
 Giant cell tumor of the bone 
Orthopaedics in the operating room                                                         30 minutes 
 Total hip arthroplasty 
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 Total knee arthroplasty 
 Total shoulder arthroplasty 
 Thromboembolism- (pretest and posttest) 
Sports Injuries                                                                                           1 hour 
 Shoulder injuries 
 Elbow injuries 
 Wrist injuries 
 Hand injuries 
 Hip injuries 
 Knee injuries 
 Ankle injuries 
 Foot injuries 
  
Week 4:   Test Oncology/Orthopedic/Sports Injuries                             30 minutes 
Orthopaedic Trauma                                                                                 1.5 hours 
 Types of fractures 
 Dislocations 
 Emergency treatment 
 Complications 
 Nursing management 
  
Week 5:   Test Orthopedic Trauma                                                          30 minutes 
                  Question & Answers/Preparing for the Exam                        30 minutes 
                   Review                                                                                   1 hour 
 
 
